SYNOVIAL SARCOMA
Clinical trials for SYNOVIAL SARCOMA explained in plain language.
Never miss a new study
Get alerted when new SYNOVIAL SARCOMA trials appear
Sign up with your email to follow new studies for SYNOVIAL SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine takes aim at rare childhood cancers
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a personalized vaccine made from each patient's unique tumor proteins. It is for children and young adults with metastatic Ewing sarcoma, rhabdomyosarcoma, or synovial sarcoma who have completed standard treatment. The goal is to see if the vaccine is safe and ca…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: University Hospital Tuebingen • Aim: ⭐️ VACCINE ⭐️
Last updated May 20, 2026 11:54 UTC
-
Engineered immune cells take on rare sarcomas in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. Participants receive specially engineered immune cells (NK cells) from donated cord blood, along with chemotherapy, to see if the combination is safe and to fi…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:18 UTC
-
Personalized cell therapy shows promise for kids with rare cancers
Disease control Recruiting nowThis study tests a new treatment called afamitresgene autoleucel in children and young adults aged 2 to 21 with certain advanced cancers (synovial sarcoma, MPNST, neuroblastoma, or osteosarcoma). The treatment uses the patient's own immune cells, which are modified in a lab to be…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated May 26, 2026 06:16 UTC
-
New virus therapy aims to boost immune attack on hard-to-treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called PeptiCRAd-1, a virus designed to train the immune system to attack cancer cells, combined with the immunotherapy drug pembrolizumab. About 15 adults with certain advanced solid tumors (like melanoma, lung cancer, or sarcoma) wil…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: Valo Therapeutics Oy • Aim: Disease control
Last updated May 26, 2026 06:08 UTC
-
Last-Chance therapy: expanded access offers TECELRA® to sarcoma patients who missed commercial specs
Disease control AVAILABLEThis program gives patients with synovial sarcoma or myxoid liposarcoma access to a cell therapy (TECELRA®) that didn't meet commercial quality standards. It's for people who have no other options for re-manufacturing or cell collection. The goal is to provide treatment when stan…
Matched conditions: SYNOVIAL SARCOMA
Sponsor: USWM CT, LLC • Aim: Disease control
Last updated May 26, 2026 06:06 UTC
-
Can a booster shot for immune cells fight rare sarcomas?
Disease control Recruiting nowThis early study tests an immunotherapy drug called N-803 in 8 people with rare soft-tissue sarcomas (synovial sarcoma or myxoid/round cell liposarcoma) whose cancer got worse after a prior cell therapy. N-803 aims to wake up leftover immune cells from the earlier treatment so th…
Matched conditions: SYNOVIAL SARCOMA
Phase: EARLY_PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
Hope for rare sarcoma: new pill shows promise in Late-Stage trial
Disease control Recruiting nowThis study tests a daily pill called AL3818 (anlotinib) for people with a rare cancer called alveolar soft part sarcoma (ASPS) that has spread. The goal is to see if the drug can shrink tumors or slow the cancer. About 325 adults with ASPS are being enrolled. Participants take th…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE3 • Sponsor: Advenchen Laboratories, LLC • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New stem cell approach aims to boost immune attack on tough childhood cancers
Disease control Recruiting nowThis study tests a stem cell transplant that removes certain immune cells (alpha/beta T cells and CD19+ B cells) and adds a drug called zoledronic acid to help the donor cells fight solid tumors that have come back or not responded to treatment. It includes children and young adu…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Engineered immune cells take on sarcoma in new combo trial
Disease control Recruiting nowThis early-stage study is testing whether a new type of immune cell therapy, called HER2-CAR T cells, combined with drugs that boost the immune system (pembrolizumab or nivolumab), is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before th…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy targets tough cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment combining two experimental therapies (IMA203 and mRNA-4203) for people with advanced melanoma or synovial sarcoma that has spread or can't be removed. The main goal is to check safety and find the best dose. About 15 participants will …
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated May 18, 2026 12:13 UTC